Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its late-stage candidate for metabolic dysfunction-associated steatohepatitis (MASH). The $14.50-per-share deal ...
When you shop through retailer links on our site, we may earn affiliate commissions. 100% of the fees we collect are used to support our nonprofit mission. Learn more. For many homeowners, a range ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback